Rakuten Investment Management Inc. Makes New $37.31 Million Investment in Zimmer Biomet Holdings, Inc. $ZBH

Rakuten Investment Management Inc. acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 378,752 shares of the medical equipment provider’s stock, valued at approximately $37,307,000. Rakuten Investment Management Inc. owned 0.19% of Zimmer Biomet at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Zimmer Biomet by 1.4% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 121,213 shares of the medical equipment provider’s stock valued at $11,939,000 after purchasing an additional 1,668 shares during the period. Chicago Partners Investment Group LLC raised its stake in shares of Zimmer Biomet by 7.6% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 4,160 shares of the medical equipment provider’s stock valued at $421,000 after buying an additional 295 shares during the last quarter. Joel Isaacson & Co. LLC acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $210,000. Root Financial Partners LLC purchased a new stake in shares of Zimmer Biomet in the third quarter worth about $31,000. Finally, Horizon Bancorp Inc. IN grew its holdings in Zimmer Biomet by 60.3% during the third quarter. Horizon Bancorp Inc. IN now owns 1,836 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 691 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $86.74 on Wednesday. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. The company has a market cap of $17.19 billion, a price-to-earnings ratio of 21.47, a PEG ratio of 2.23 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.44. The firm’s fifty day simple moving average is $91.53 and its two-hundred day simple moving average is $96.40.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the previous year, the company earned $1.74 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Stifel Nicolaus set a $110.00 target price on shares of Zimmer Biomet in a research note on Wednesday, November 5th. BTIG Research restated a “buy” rating and set a $112.00 price target on shares of Zimmer Biomet in a research report on Thursday, January 8th. Robert W. Baird reaffirmed a “neutral” rating and issued a $100.00 price objective (down previously from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Finally, Royal Bank Of Canada lowered their target price on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $107.33.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.